Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
|Articles|December 15, 2021
Daily Medication Pearl: Ondansetron Hydrochloride (Zofran)
Author(s)Saro Arakelians, PharmD
Zofran aids in the prevention of nausea and vomiting.
Advertisement
Medication Pearl of the Day: Ondansetron Hydrochloride (Zofran)
Indication: Zofran is a 5-HT3 receptor antagonist indicated for the prevention of nausea and vomiting.
Insight:
- Dosing: Take 1 tablet every day or as needed prescribed by the provider.
- Dosage forms: Tablets 4 mg and 8 mg (orally disintegrating tablets available), oral solution 4 mg/5 mL.
- Adverse events (AEs): The most common AEs in adults are headache, malaise/fatigue, constipation, and diarrhea.
- Mechanism of action: Ondansetron is a selective 5-HT3 receptor antagonist.
- Manufacturer: GSK
Sources:
Advertisement
Related to this article
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
2
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
5